- Home
- PRCT
as of 03-19-2026 3:42pm EST
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 1.5B | IPO Year: | 2021 |
| Target Price: | $35.44 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.72 | EPS Growth: | 1.71 |
| 52 Week Low/High: | $19.35 - $64.89 | Next Earning Date: | 04-23-2026 |
| Revenue: | $308,054,000 | Revenue Growth: | 37.22% |
| Revenue Growth (this year): | 32.85% | Revenue Growth (next year): | 24.66% |
| P/E Ratio: | -15.22 | Index: | N/A |
| Free Cash Flow: | -58341000.0 | FCF Growth: | N/A |
AI-Powered PRCT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of PROCEPT BioRobotics Corporation (PRCT)
EVP, CLO, CORP. SEC.
Avg Cost/Share
$25.98
Shares
5,363
Total Value
$139,230.77
Owned After
105,354
EVP, CFO
Avg Cost/Share
$28.15
Shares
706
Total Value
$19,876.16
Owned After
151,558
SEC Form 4
EVP, CLO, CORP. SEC.
Avg Cost/Share
$28.15
Shares
304
Total Value
$8,558.57
Owned After
105,354
SEC Form 4
EVP, CLO, CORP. SEC.
Avg Cost/Share
$26.17
Shares
3,243
Total Value
$83,197.26
Owned After
105,354
Director
Avg Cost/Share
$24.80
Shares
98,699
Total Value
$2,422,890.75
Owned After
371,144
Director
Avg Cost/Share
$23.72
Shares
160,317
Total Value
$3,781,503.47
Owned After
371,144
EVP, CFO
Avg Cost/Share
$23.70
Shares
6,721
Total Value
$159,300.47
Owned After
151,558
SEC Form 4
EVP, CLO, CORP. SEC.
Avg Cost/Share
$23.70
Shares
6,892
Total Value
$163,353.49
Owned After
105,354
SEC Form 4
Director
Avg Cost/Share
$25.92
Shares
167,246
Total Value
$4,278,548.73
Owned After
371,144
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 19, 2026 | Sell | $25.98 | 5,363 | $139,230.77 | 105,354 | |
| Waters Kevin | PRCT | EVP, CFO | Mar 17, 2026 | Sell | $28.15 | 706 | $19,876.16 | 151,558 | |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 17, 2026 | Sell | $28.15 | 304 | $8,558.57 | 105,354 | |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 10, 2026 | Sell | $26.17 | 3,243 | $83,197.26 | 105,354 | |
| Desai Antal Rohit | PRCT | Director | Mar 9, 2026 | Buy | $24.80 | 98,699 | $2,422,890.75 | 371,144 | |
| Desai Antal Rohit | PRCT | Director | Mar 6, 2026 | Buy | $23.72 | 160,317 | $3,781,503.47 | 371,144 | |
| Waters Kevin | PRCT | EVP, CFO | Mar 6, 2026 | Sell | $23.70 | 6,721 | $159,300.47 | 151,558 | |
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Mar 6, 2026 | Sell | $23.70 | 6,892 | $163,353.49 | 105,354 | |
| Desai Antal Rohit | PRCT | Director | Mar 5, 2026 | Buy | $25.92 | 167,246 | $4,278,548.73 | 371,144 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 25, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 25, 2026 · 100% conf.
1D
+3.57%
$28.83
Act: -15.12%
5D
+5.10%
$29.26
Act: -4.60%
20D
+8.85%
$30.30
prct-202602250001588978false00015889782026-02-252026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026
PROCEPT BIOROBOTICS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
150 Baytech Drive San Jose, California 95134 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (650) 232-7200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.00001 par value per share PRCT The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On February 25, 2026, PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.Description 99.1Press Release of PROCEPT BioRobotics Corporation, dated February 25, 2026
104Cover Page Interactive Data File, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROCEPT BIOROBOTICS CORPORATION
Date: February 25, 2026 By: /s/ Alaleh Nouri Alaleh Nouri
Chief Legal Officer and Secretary
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
Q3 2025 Earnings
8-KNov 4, 2025
prct-202511040001588978false00015889782025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025
PROCEPT BIOROBOTICS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
150 Baytech Drive San Jose, California 95134 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (650) 232-7200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.00001 par value per share PRCT The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On November 4, 2025, PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.Description 99.1Press Release of PROCEPT BioRobotics Corporation, dated November 4, 2025
104Cover Page Interactive Data File, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROCEPT BIOROBOTICS CORPORATION
Date: November 4, 2025 By: /s/ Alaleh Nouri Alaleh Nouri
Chief Legal Officer and Secretary
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
Q2 2025 Earnings
8-KAug 6, 2025
prct-202508060001588978false00015889782025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025
PROCEPT BIOROBOTICS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 001-40797 26-0199180 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
150 Baytech Drive San Jose, California 95134 (Address of principal executive offices, including Zip Code) Registrant’s telephone number, including area code: (650) 232-7200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.00001 par value per share PRCT The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On August 6, 2025, PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.Description 99.1Press Release of PROCEPT BioRobotics Corporation, dated August 6, 2025
104Cover Page Interactive Data File, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROCEPT BIOROBOTICS CORPORATION
Date: August 6, 2025 By: /s/ Alaleh Nouri Alaleh Nouri
Chief Legal Officer and Secretary
Compare PRCT vs Leading Stocks
See how PRCT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PRCT PROCEPT BioRobotics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.